Aaron S. Mansfield MD

Aaron S. Mansfield, M.D., is a medical oncologist at Mayo Clinic with a focus on thoracic malignancies and early therapeutics. He is co-director of the Precision Cancer Therapeutics Program within the Mayo Clinic Center for Individualized Medicine.

Aaron S. Mansfield has played a significant role, including principal investigator, in clinical trials leading to Food and Drug Administration approval of agents for thoracic malignancies. These include atezolizumab for small cell lung cancer, trametinib for rearranged during transfection (RET) fusion-positive non-small cell lung cancer, and the combination of ipilimumab and nivolumab for mesothelioma.

Aaron S. Mansfield's laboratory runs many translational projects to discover and validate biomarkers in thoracic malignancies. Further, Dr. Mansfield has received funding from multiple peer-reviewed organizations, including the National Cancer Institute, the Department of Defense, and the Mark Foundation for Cancer Research.